Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT03319901 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03319901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03319901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 30, 2017
Completion date
May 30, 2028
Enrollment
82 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia